NCT03966651
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03966651
Title A Clinical Study Evaluating the Safety of Peptide Receptor Radionuclide Therapy (PRRT) With 177Lu-DOTA0-Tyr3-Octreotate in Children With Refractory or Recurrent Neuroblastoma Expressing Somatostatin Receptors. (NEUROBLU 02)
Acronym NEUROBLU 02
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Institut Claudius Regaud
Indications
Therapies
Age Groups: adult | child
Covered Countries FRA


No variant requirements are available.